{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T03:37:48Z","timestamp":1772077068974,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.3816\/clml.2010.n.058","type":"journal-article","created":{"date-parts":[[2010,8,14]],"date-time":"2010-08-14T06:11:22Z","timestamp":1281766282000},"page":"281-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase II Study of Sunitinib in Patients With Primary or Post\u2013Polycythemia Vera\/Essential Thrombocythemia Myelofibrosis"],"prefix":"10.3816","volume":"10","author":[{"given":"Effrosyni","family":"Apostolidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.058_bib1","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.058_bib2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.058_bib3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1365-2141.1998.00833.x","article-title":"Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups","volume":"102","author":"Cervantes","year":"1998","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.058_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.058_bib5","first-page":"2831","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.058_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/10428199509054751","article-title":"TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders","volume":"20","author":"Martyre","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.n.058_bib7","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.058_bib8","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood.V96.10.3374","article-title":"Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia","volume":"96","author":"Mesa","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.058_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-0609.2004.00355.x","article-title":"Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia","volume":"74","author":"Ho","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.058_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2141.1994.tb04970.x","article-title":"Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis","volume":"88","author":"Martyr\u00e9","year":"1994","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.058_bib11","unstructured":"SU011248 [Investigator's Brochure]. Pfizer IaA. New York, NY; 2005"},{"key":"10.3816\/CLML.2010.n.058_bib12","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.058_bib13","first-page":"1329","article-title":"Su-11248 Sugen","volume":"5","author":"Sakamoto","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.3816\/CLML.2010.n.058_bib14","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","article-title":"A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease","volume":"105","author":"Fiedler","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.058_bib15","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","article-title":"A population pharmacokinetic metabolite (SU12662) in healthy volunteers and oncology patients","volume":"15","author":"Houk","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.058_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.058_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/10245330701554664","article-title":"Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases","volume":"12","author":"Panteli","year":"2007","journal-title":"Hematology"},{"key":"10.3816\/CLML.2010.n.058_bib18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2141.2007.06885.x","article-title":"Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations","volume":"140","author":"Boveri","year":"2008","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.058_bib19","first-page":"1454","article-title":"Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia","volume":"89","author":"Arora","year":"2004","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.058_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.2001.02883.x","article-title":"A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia","volume":"114","author":"Mesa","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.058_bib21","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration","volume":"60","author":"Wood","year":"2000","journal-title":"Cancer Res"},{"key":"10.3816\/CLML.2010.n.058_bib22","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.leukres.2006.12.001","article-title":"PTK787\/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia","volume":"31","author":"Giles","year":"2007","journal-title":"Leuk Res"},{"key":"10.3816\/CLML.2010.n.058_bib23","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.11315","article-title":"Phase II study of SU5416\u2014a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor\u2014in patients with refractory myeloproliferative diseases","volume":"97","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.058_bib24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","article-title":"Sunitinib: from rational design to clinical efficacy","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:58Z","timestamp":1761870178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S2152265011700350"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.058","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Study of Sunitinib in Patients With Primary or Post\u2013Polycythemia Vera\/Essential Thrombocythemia Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}